Xenitra Limited Expands Strategic Partnership with Rockcheck to Strengthen China Growth
Xenitra Limited (ASX: XEN) has entered into two agreements with Rockcheck Group to deepen its strategic presence in China’s high-growth nutrition and FMCG segment. The primary agreement targets Danone product sales of 140 million RMB (~AU$30 million) over a one-year period starting May 2026, with a potential three-year extension subject to early performance.
Rockcheck has been a key partner since 2023, contributing over AU$10 million in FY26 sales to date. Additionally, Xenitra’s Australian trading subsidiary has been designated as an authorised supplier, enabling direct B2B procurement into Rockcheck’s extensive corporate network. This framework enhances Xenitra’s distribution capabilities beyond ecommerce channels, strengthening its multi-channel model. The partnership reinforces the company’s nutritionals segment, a core revenue driver, while supporting its broader strategy to scale operations efficiently and move towards profitability through expanded product offerings and deeper market integration.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Xenitra Limited Expands Strategic Partnership with Rockcheck to Strengthen China Growth
Xenitra Limited (ASX: XEN) has entered into two agreements with Rockcheck Group to deepen its strategic presence in China’s high-growth nutrition and FMCG segment. The primary agreement targets Danone product sales of 140 million RMB (~AU$30 million) over a one-year period starting May 2026, with a potential three-year extension subject to early performance.
Rockcheck has been a key partner since 2023, contributing over AU$10 million in FY26 sales to date. Additionally, Xenitra’s Australian trading subsidiary has been designated as an authorised supplier, enabling direct B2B procurement into Rockcheck’s extensive corporate network. This framework enhances Xenitra’s distribution capabilities beyond ecommerce channels, strengthening its multi-channel model. The partnership reinforces the company’s nutritionals segment, a core revenue driver, while supporting its broader strategy to scale operations efficiently and move towards profitability through expanded product offerings and deeper market integration.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au